Clinical significance of altered S100A2 expression in gastric cancer

Zhao,Ying; Zhang,Tian-Biao; Wang,Qiang

doi:10.3892/or.2013.2236

Clinical significance of altered S100A2 expression in gastric cancer

Authors:
- Ying Zhao
- Tian-Biao Zhang
- Qiang Wang
View Affiliations

Affiliations: Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China
Published online on: January 15, 2013 https://doi.org/10.3892/or.2013.2236
Pages: 1556-1562

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The S100A2 gene has been reported to be a putative tumor‑suppressor gene. Nevertheless, overexpression of S100A2 has been found in certain types of cancer. This study investigated S100A2 expression in tissue specimens of gastritis, intestinal metaplasia, adenomatous dysplasia and gastric cancer to determine its association with clinical features. A serial of tissue samples (gastritis, intestinal metaplasia, adenomatous dysplasia and gastric cancer samples) were used for quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR), western blotting and immunohistochemical analyses of S100A2 expression. The data revealed that there was a gradual loss of S100A2 expression from gastritis, intestinal metaplasia and dysplasia to cancer tissue specimens (p<0.001). In gastric cancer samples, loss of S100A2 expression was associated with increased tumor size, depth of invasion, lymph node metastasis and a poor prognosis (p<0.001). However, the intestinal type of gastric cancer expressed more S100A2 protein than the diffuse type (p<0.001). In conclusion, data from the present study demonstrated that loss of S100A2 expression contributes to gastric cancer development and progression; therefore, the determination of S100A2 expression levels may help to predict the carcinogenesis and aggressiveness of gastric cancer as well as patient survival.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer Clin. 61:69–90. 2011. View Article : Google Scholar
2	Wolf S, Haase-Kohn C and Pietzsch J: S100A2 in carcinogenesis: a friend or a foe? Amino Acids. 41:849–861. 2011. View Article : Google Scholar : PubMed/NCBI
3	Mueller A, Schäfer BW, Ferrari S, Weibel M, Makek M, Höchli M and Heizmann CW: The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem. 280:29186–29193. 2005. View Article : Google Scholar : PubMed/NCBI
4	Lapi E, Iovino A, Fontemaggi G, Soliera AR, Iacovelli S, Sacchi A, Rechavi G, Givol D, Blandino G and Strano S: S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. Oncogene. 25:3628–3637. 2006. View Article : Google Scholar : PubMed/NCBI
5	Tsai ST, Jin YT, Tsai WC, Wang ST, Lin YC, Chang MT and Wu LW: S100A2, a potential marker for early recurrence in early-stage oral cancer. Oral Oncol. 41:349–357. 2005. View Article : Google Scholar : PubMed/NCBI
6	Nagy N, Brenner C, Markadieu N, Chaboteaux C, Camby I, Schäfer BW, Pochet R, Heizmann CW, Salmon I, Kiss R and Decaestecker C: S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest. 81:599–612. 2001. View Article : Google Scholar : PubMed/NCBI
7	Ohuchida K, Mizumoto K, Miyasaka Y, Yu J, Cui L, Yamaguchi H, Toma H, Takahata S, Sato N, Nagai E, Yamaguchi K, Tsuneyoshi M and Tanaka M: Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J Pathol. 213:275–282. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE and Simm A: S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer. 43:1935–1943. 2007. View Article : Google Scholar : PubMed/NCBI
9	Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K and Miyauchi A: Expression of S100A2 and S100A6 in thyroid carcinomas. Histopathology. 46:569–575. 2005. View Article : Google Scholar : PubMed/NCBI
10	Sobin LH and Wittekind CH: TNM Classification of Malignant Tumors. 6th edition. Hoboken NJ: John Wiley & Sons; NJ: 2002
11	Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF and Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch. 452:525–534. 2008. View Article : Google Scholar : PubMed/NCBI
12	Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K and Takano Y: Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol. 60:273–277. 2007. View Article : Google Scholar : PubMed/NCBI
13	Luo J, Zhu Y, Yang G, Gong L, Wang B and Liu H: Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma. Diagn Cytopathol. 39:752–757. 2007. View Article : Google Scholar : PubMed/NCBI
14	Lee OJ, Hong SM, Razvi MH, Peng D, Powell SM, Smoklin M, Moskaluk CA and El-Rifai W: Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas. Neoplasia. 8:843–850. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kwon YW, Chang IH, Kim KD, Kim YS, Myung SC, Kim MK and Kim TH: Significance of S100A2 and S100A4 expression in the progression of prostate adenocarcinoma. Korean J Urol. 51:456–462. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cao LY, Yin Y, Li H, Jiang Y and Zhang HF: Expression and clinical significance of S100A2 and p63 in esophageal carcinoma. World J Gastroenterol. 15:4183–4188. 2009. View Article : Google Scholar : PubMed/NCBI
17	Imazawa M, Hibi K, Fujitake S, Kodera Y, Ito K, Akiyama S and Nakao A: S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. Anticancer Res. 25:1247–1250. 2005.PubMed/NCBI
18	Zheng HC, Xu XY, Yu M, Takahashi H, Masuda S and Takano Y: The role of Reg IV gene and its encoding product in gastric carcinogenesis. Hum Pathol. 41:59–69. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhang YC: Geographic pathology of gastric dysplasia in China. Semin Surg Oncol. 10:100–106. 1994. View Article : Google Scholar : PubMed/NCBI
20	Wicki R, Franz C, Scholl FA, Heizmann CW and Schäfer BW: Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium. 22:243–254. 1997. View Article : Google Scholar : PubMed/NCBI
21	Rehman I, Cross SS, Catto JW, Leiblich A, Mukherjee A, Azzouzi AR, Leung HY and Hamdy FC: Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate. 65:322–330. 2005. View Article : Google Scholar : PubMed/NCBI
22	Feng G, Xu X, Youssef EM and Lotan R: Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res. 61:7999–8004. 2001.PubMed/NCBI
23	Zhang X, Hunt JL, Shin DM and Chen ZG: Down-regulation of S100A2 in lymph node metastases of head and neck cancer. Head Neck. 29:236–243. 2007. View Article : Google Scholar : PubMed/NCBI
24	Suzuki F, Oridate N, Homma A, Nakamaru Y, Nagahashi T, Yagi K, Yamaguchi S, Furuta Y and Fukuda S: S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity. Oncol Rep. 14:1493–1498. 2005.PubMed/NCBI
25	Matsumoto K, Irie A, Satoh T, Ishii J, Iwabuchi K, Iwamura M, Egawa S and Baba S: Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology. 70:602–607. 2007. View Article : Google Scholar : PubMed/NCBI
26	Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T, Heizmann CW, Aburatani H, Moriyama S, Moriyama H, Nishimura Y, Funata N and Fukayama M: Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci. 96:844–857. 2005. View Article : Google Scholar
27	Almadori G, Bussu F, Galli J, Rigante M, Lauriola L, Michetti F, Maggiano N, Schafer BW, Heizmann CW, Ranelletti FO and Paludetti G: Diminished expression of S100A2, a putative tumour suppressor, is an independent predictive factor of neck node relapse in laryngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 38:16–22. 2009.PubMed/NCBI
28	Lauriola L, Michetti F, Maggiano N, Galli J, Cadoni G, Schäfer BW, Heizmann CW and Ranelletti FO: Prognostic significance of the Ca(2+) binding protein S100A2 in laryngeal squamous-cell carcinoma. Int J Cancer. 89:345–349. 2000.
29	Wang H, Zhang Z, Li R, Ang KK, Zhang H, Caraway NP, Katz RL and Jiang F: Overexpression of S100A2 protein as a prognostic marker for patients with stage I non-small cell lung cancer. Int J Cancer. 116:285–290. 2005. View Article : Google Scholar : PubMed/NCBI
30	Kyriazanos ID, Tachibana M, Dhar DK, Shibakita M, Ono T, Kohno H and Nagasue N: Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus. Oncol Rep. 9:503–510. 2002.PubMed/NCBI